Johnson and Johnson

View All

pharma-news-updates-for-biomarin-gilead-alzheon
FDA rejects BioMarin’s Valoctocogene Roxaparvovec; J&J inks $6.5B deal; Alzheon bags $47M; Research updates on diabetes

FDA rejects BioMarin's gene therapy and Gilead's filgotinib over concerns The FDA refused to approve BioMarin's hemophilia A gene therapy valoctocogene roxaparvovec. The U.S. regulator that had earlier told there was no requirement of an AdComm for the drug, aka, valrox, has issued a complete response (CRL) lett...

Find More

pharma-news
Merck supports Peloton Therapeutics; Thermo Fisher, WuXi and Mayo Clinic join hands; JNJ’s anti-BCMA CAR-T sweeps multiple myeloma aside; Tafinlar-Mekinist combo of Novartis receives a boost

Merck supports Peloton Therapeutics with positive kidney cancer data Merck is revealing the data from a phase 2 study of a HIF-2α inhibitor after a year betting USD 1.05 billion on Peloton Therapeutics, and the deal is promising.  The drug limited tumour growth in 43% and shrank tumors in 28% of patients...

Find More

Non-Small Cell Lung Cancer Market Insights
Novel mutation-targeting therapies in the horizon to relieve the global healthcare burden NSCLC poses

Non-small cell lung cancer market is anticipated to increase in the 7MM from USD 9,730 million in 2017 by 2030. Worldwide, cancer claimed the lives of approximately 9.6 million people in 2018 as per WHO, with lung cancer being the most commonly diagnosed one and accounting for the highest number of deaths (1.76...

Find More

COVID-19 Pharma News
J&J’s COVID-19 Vaccine; GigaGen COVID-19 therapy; FDA approved Abbott’s POC test; Cobra Bio raises $ 3.3 M

Johnson & Johnson is fast-forwarding its vaccine development program for COVID-19.  The healthcare company has selected a lead vaccine candidate and is planning to begin human trials in September, with first batches available under potential emergency use authorization in the first part of 2021. The ...

Find More

pharma news
Sage seeks to save depression drug; Regeneron aims clinical trial; J&J sets sights for COVID-19 trial

Sage Therapeutics seeking out to save flunked depression drug  Sage Therapeutics has strategized on how to come back from the phase 3 failure of SAGE-217 in major depressive disorder. The plan focuses on three short-term studies Sage contemplates that may enable it to bring the GABA receptor positive allost...

Find More

Healthcare scenario in MENA region
Booming Healthcare sector in MENA: Lucrative opportunity for Global pharma players

The Middle-East and North-Africa region (MENA), which encompasses some of the world’s wealthiest economies, extends unparalleled opportunities to multinational corporations with expertise in medical devices. There is a conspicuous disparity in the economic prowess across the countries, but most of them have shown r...

Find More

PHARMA NEWS
J&J collaborates with BARDA; Virus kills pancreatic cancer cells; ALX raises USD 105 million for CD47 drug

J&J collaborates with BARDA to accelerate coronavirus vaccine program Johnson & Johnson has collaborated with the U.S. Biomedical Advanced Research and Development Authority (BARDA) to produce a vaccine against novel coronavirus. J&J is attempting to pool money and resources with BARDA in order to qu...

Find More

Coronavirus
Wuhan Coronavirus: A global emergency

An outbreak of a mysterious viral infection, 2019-nCoV – coronavirus, has set the whole world on toes, claiming the lives of more than 800 people in China, surpassing the death toll caused from SARS, reports the Chinese government.  An infection with the symptoms more or less like pneumonia, known by the name ...

Find More

Pharma News
Thumbs down to NKTR-181, Lilly expands its insulin armamentarium

The US FDA has voted down Nektar Therapeutics’ opioid painkiller NKTR-181, designed to treat lower back pain.  The FDA’s Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee unanimously has decided not to recommend the use of the painkiller, ta...

Find More

Hairy cell leukaemia
What to expect in the Coming Years for Hairy Cell Leukemia Therapy landscape?

Every 3 minutes, one person in the United States (U.S.) is diagnosed with blood cancer, as estimated by The Leukemia & Lymphoma Society (LLS). A total number of 176,200 people are expected to be diagnosed with leukaemia, lymphoma or myeloma in 2019. Out of which, 61,780 people are expected to be diagnosed with ...

Find More